John Milligan, Gilead’s new CEO, will face many challenges, including pressures over competition and pricing for the company’s hepatitis C pills. Gilead sales have risen nearly 3½ times to $32.2 billion last year.
Gilead's New Ceo Faces Pressures On Hepatitis C Pills
WSJ.com: Management, Wall Street Journal: Business: Management
Mon, 06/06/2016 - 5:57pm
Welcome to Wopular
Wopular is an
online newspaper rack,
giving you a summary view of the top headlines from the top news sites.
Senh Duong (Founder)
Wopular,
MWB,
RottenTomatoes
MoviesWithButter : Our Sister Site
- "Expendables 4" Starts Shooting This Fall, Says Randy Couture at the Arnold Sports Festival more
- “Expendables 4” Gets Funding Interest from “Ip Man 3” Financier more
- "Ip Man 3" Distributor Suspected of Box Office Fraud, Parent Company Loses $200M in Market Cap more
- Yen Targets "Ip Man 4" for 2018 Release; Discusses Film with Director, Producer more
- "Ip Man 3" Shatters Expectations with $72M Opening [China Box Office] more